Jounce Therapeutics (JNCE) to Release Quarterly Earnings on Tuesday
Jounce Therapeutics (NASDAQ:JNCE) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, November 13th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter.
Jounce Therapeutics (NASDAQ:JNCE) last issued its earnings results on Friday, August 10th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.23. The business had revenue of $19.38 million for the quarter, compared to analyst estimates of $12.47 million. Jounce Therapeutics had a negative net margin of 50.54% and a negative return on equity of 23.27%. On average, analysts expect Jounce Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of NASDAQ JNCE opened at $4.81 on Friday. The firm has a market cap of $178.47 million, a P/E ratio of -8.44 and a beta of 4.97. Jounce Therapeutics has a 12-month low of $4.03 and a 12-month high of $29.25.
About Jounce Therapeutics
Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.
Further Reading: What is a Call Option?
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.